Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp

In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antiviral research Ročník 226; s. 105873
Hlavní autoři: Wong, Gary, Bienes, Kathrina Mae, XIII, Ara, Fausther-Bovendo, Hugues, Kobinger, Gary P.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.06.2024
Témata:
Africa, Western - epidemiology
Animals
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - immunology
Antibodies, Viral - therapeutic use
Disease Outbreaks
Ebola Virus
Ebolavirus - drug effects
Ebolavirus - immunology
EBOV
Hemorrhagic Fever, Ebola - drug therapy
Hemorrhagic Fever, Ebola - immunology
Humans
mAbs
Monoclonal antibodies
ZMapp
Africa, Western
Monoclonal antibodies
EBOV
Ebola Virus
ZMapp
mAbs
ISSN:0166-3542, 1872-9096, 1872-9096
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013–2016 West Africa outbreak. This review recounts the history of a candidate mAb treatment, ZMapp, beginning with its emergency use in the 2013–2016 outbreak and advancing to randomized controlled trials into the 2018–2020 African outbreak. We end with a brief discussion of the hurdles and promise toward mAb therapeutic use against infectious disease.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0166-3542
1872-9096
1872-9096
DOI:10.1016/j.antiviral.2024.105873